Publications by authors named "Abbie Fields"

Claim this Profile
U
Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: a clinicopathologic study of 84 patients originally classified as FIGO stage II.
Jeffrey D Seidman, Jonathan A Cosin, Brant G Wang, Skylar Alsop, Anna Yemelyanova, Abbie Fields

Gynecol Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
Abbie L Fields, Mark H Einstein, Akiva P Novetsky, Juliana Gebb, Gary L Goldberg

Gynecol Oncol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer.
Akiva P Novetsky, Mark H Einstein, Gary L Goldberg, Susan M Hailpern, Evan Landau, Abbie L Fields

Gynecol Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer.
Mark H Einstein, Akiva P Novetsky, Madhur Garg, Susan M Hailpern, Gloria S Huang, Abbie L Fields

Cancer· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003).
Gary L Goldberg, Paniti Sukumvanich, Mark H Einstein, Harriet O Smith, Patrick S Anderson, Abbie L Fields

Gynecol Oncol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Sanjay Goel, Kavita Desai, Manuel Macapinlac, Scott Wadler, Gary Goldberg, Abbie Fields

Invest New Drugs· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
D Yi-Shin Kuo, Patrick Timmins, Stephanie V Blank, Abbie L Fields, Gary L Goldberg

Gynecol Oncol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
Brij M Sood, Joan Jones, Sajel Gupta, Dineo Khabele, Chandan Guha, Abbie Fields

Int J Radiat Oncol Biol Phys· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.
Sanjay Goel, Kavita Desai, Anca Bulgaru, Abbie Fields, Gary Goldberg

Clin Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies.
Dineo Khabele, Carolyn D Runowicz, Abbie L Fields, Patrick S Anderson, Gary L Goldberg

Gynecol Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current therapies in ovarian cancer.
Abbie L Fields, Carolyn D Runowicz

Cancer Invest· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy.
Brij M Sood, Giridhar R Gorla, Madhur Garg, Patrick S Anderson, Abbie L Fields

Cancer· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.
Brij M Sood, Giridhar Gorla, Sajel Gupta, Madhur Garg, Shivaji Deore, Abbie L Fields

Int J Radiat Oncol Biol Phys· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix.
Jonathan J Beitler, Patrick Anderson, Hilda Haynes, Brij Sood, Abbie Fields

Int J Radiat Oncol Biol Phys· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis